Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

The results of Look AHEAD do not row against the implementation of lifestyle changes in patients with type 2 diabetes.

Annuzzi G, Rivellese AA, Bozzetto L, Riccardi G.

Nutr Metab Cardiovasc Dis. 2014 Jan;24(1):4-9. doi: 10.1016/j.numecd.2013.12.001. Epub 2013 Dec 20.

PMID:
24388434
2.

Drug treatment of obesity in cardiovascular disease.

Charakida M, Finer N.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):93-104. doi: 10.2165/11599000-000000000-00000. Review.

PMID:
22292446
3.

Diabesity: therapeutic options.

Colagiuri S.

Diabetes Obes Metab. 2010 Jun;12(6):463-73. doi: 10.1111/j.1463-1326.2009.01182.x. Review.

PMID:
20518802
4.

Advances in the treatment of nonalcoholic fatty liver disease.

Mehta SR.

Ther Adv Endocrinol Metab. 2010 Jun;1(3):101-15. doi: 10.1177/2042018810379587.

5.

Advances in the treatment of prediabetes.

Matfin G, Pratley RE.

Ther Adv Endocrinol Metab. 2010 Feb;1(1):5-14. doi: 10.1177/2042018810366429.

6.

[Therapeutic options for treatment of cardiometabolic risk].

Stokić E, Tomić-Naglić D, Derić M, Jorga J.

Med Pregl. 2009;62 Suppl 3:54-8. Review. Serbian.

PMID:
19702117
7.

The endocannabinoid system as a target for obesity treatment.

Aronne LJ, Pagotto U, Foster GD, Davis SN.

Clin Cornerstone. 2008;9(1):52-64; discussion 65-6.

PMID:
19046740
8.
9.

Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review.

Lloret-Linares C, Greenfield JR, Czernichow S.

Diabet Med. 2008 Oct;25(10):1142-50. doi: 10.1111/j.1464-5491.2008.02550.x. Review.

PMID:
19046191
10.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
11.

Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.

Chou KM, Huang BY, Fanchiang JK, Chen CH.

Chang Gung Med J. 2007 Nov-Dec;30(6):538-46.

12.

Emerging concepts in the medical and surgical treatment of obesity.

Aylwin S, Al-Zaman Y.

Front Horm Res. 2008;36:229-59. doi: 10.1159/0000115368. Review.

PMID:
18230906
13.

Strategies to reduce vascular risk associated with obesity.

Bodary PF, Iglay HB, Eitzman DT.

Curr Vasc Pharmacol. 2007 Oct;5(4):249-58. Review.

PMID:
17979791
14.

Challenges and strategies in managing cardiometabolic risk.

Repas TB.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S4-11. Review.

PMID:
17784529
15.

Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.

Lee M, Aronne LJ.

Am J Cardiol. 2007 Feb 19;99(4A):68B-79B. Epub 2006 Dec 27. Review.

PMID:
17307059
16.

Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.

Shi YF, Pan CY, Hill J, Gao Y.

Diabet Med. 2005 Dec;22(12):1737-43.

PMID:
16401321
17.

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.

Nelson RH, Miles JM.

Expert Opin Pharmacother. 2005 Nov;6(14):2483-91. Review.

PMID:
16259579
18.

[Obesity and type 2 diabetes].

Rorive M, Letiexhe MR, Scheen AJ, Ziegler O.

Rev Med Liege. 2005 May-Jun;60(5-6):374-82. Review. French.

PMID:
16035297
19.

Prevention of type 2 diabetes.

Laakso M.

Curr Mol Med. 2005 May;5(3):365-74. Review.

PMID:
15892655
20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk